Aerie Pharmaceuticals (Germany) Profile

EUR 0.000001  0.00%

Aerie Pharmaceuticals Summary

Aerie Pharmaceuticals (0P0) is traded on Frankfurt Stock Exchange in Germany. It is located in 4301 Emperor Boulevard and employs 160 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.67 B. Aerie Pharmaceuticals has 36.43 M outstanding shares. AERIE PHARMACEUT has accumulated about 249.66 M in cash with (93.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.32.
Check Aerie Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 75.33%30 days 43.87  about 24.62%
Based on normal probability distribution, the odds of Aerie Pharmaceuticals to move above current price in 30 days from now is about 24.62% (This Aerie Pharmaceuticals probability density function shows the probability of Aerie Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Aerie Pharmaceuticals Risk Profiles

Key Fundamentals

Aerie Pharmaceuticals Against Markets

Current Ratings

Aerie Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 32% 
Equity ratings for Aerie Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina. Aerie Pharmaceuticals is traded on Frankfurt Stock Exchange in Germany. more
NameAerie Pharmaceuticals
Chairman of the Board, CEOVicente AnidoView All
Macroaxis Advice
InstrumentGermany Stock View All
Business Address4301 Emperor Boulevard
ExchangeFrankfurt Stock Exchange
Contact Number919 237 5300
CurrencyEUR - Euro

Diversify with Aerie Pharmaceuticals

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Aerie Pharmaceuticals to your portfolio


Aerie Pharmaceuticals Corporate Directors
Julie McHugh Independent Director, MBA
Benjamin McGraw Independent Director, Ph.D
Anand Mehra Director, Ph.D
Check also Trending Equities. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.